Section Arrow
ALMS.NASDAQ
- Alumis Inc.
Quotes are at least 15-min delayed:2026/07/10 14:35 EDT
Regular Hours
Last
 28.46
-1.84 (-6.07%)
Day High 
30.24 
Prev. Close
30.3 
1-M High
31.35 
Volume 
536.34K 
Bid
28.38
Ask
28.5
Day Low
27.4201 
Open
30.24 
1-M Low
19.835 
Market Cap 
3.86B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 27.64 
20-SMA 25.36 
50-SMA 23.65 
52-W High 31.35 
52-W Low 3.245 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.78/-2.93
Enterprise Value
3.90B
Balance Sheet
Book Value Per Share
4.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
24.05M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.085+0.025+2.36%-- 
RXRXRecursion Pharmaceuticals3.565-0.195-5.19%-- 
HUMAHumacyte0.7093+0.009+1.29%-- 
GOSSGossamer Bio0.16915-0.00585-3.34%-- 
IBRXImmunityBio8.225-0.645-7.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005,a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.